Understanding PIQRAY

PIQRAY® (alpelisib) tablets + fulvestrant

What Is PIQRAY?

PIQRAY is a prescription medicine that is:

 

  • The first and only treatment used in combination with the medicine fulvestrant to treat women who have gone through menopause, and men, to treat HR+, HER2- advanced or metastatic breast cancer (mBC) with an abnormal PIK3CA gene whose disease has progressed on or after endocrine (hormone) therapy.
  • A biomarker-driven treatment approach, which means that your health care provider will test your cancer for an abnormal "PIK3CA" gene to make sure that PIQRAY is right for you.
Metastatic breast cancer and PIK3CA mutation statistics Metastatic breast cancer and PIK3CA mutation statistics

Who Is PIQRAY For?

Postmenopausal women, or men, who:

 

  • Have tested positive for a certain mutation, or abnormality, in a gene called PIK3CA (mutations in PIK3CA have been linked to cancer growth)
  • Have HR+, HER2- advanced or metastatic breast cancer
  • Have progressed on or after hormone therapy

Your health care provider will test your cancer for an abnormal "PIK3CA" gene to make sure that PIQRAY is right for you.

 

It is not known if PIQRAY is safe and effective in children.

How Does PIQRAY Work?

How does PIQRAY work? PIQRAY addresses proteins made from a mutated (or abnormal) PIK3CA gene.

PIQRAY® (alpelisib) and fulvestrant PIQRAY works together with fulvestrant (a hormone therapy) to treat your HR+, HER2- mBC with a PIK3CA mutation. PIQRAY affects cancer cells, but can also affect healthy cells.

 

Although PIQRAY has been studied in patients with HR+, HER2- mBC, how PIQRAY works has only been demonstrated in laboratory studies.